Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Raubitschek

Showing results (51-60 of 89) with videos related to

Pageof 9
Sort By:
Cancer Research|February 1, 1990
Innovations that influence the pharmacology of monoclonal antibody guided tumor targetingJ Schlom, P H Hand, J W Greiner, et al.
Journal of Immunological Methods|June 1, 2001
Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applicationsP J Yazaki, L Shively, C Clark, et al.
Bioconjugate Chemistry|April 21, 2001
Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragmentsP J Yazaki, A M Wu, S W Tsai, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|November 1, 1992
A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapyJ R Lange, A A Raubitschek, B A Pockaj, et al.
Medical Physics|June 9, 1999
Intrapatient consistency of imaging biodistributions and their application to predicting therapeutic doses in a phase I clinical study of 90Y-based radioimmunotherapyK G Clarke, T L Odom-Maryon, L E Williams, et al.
Protein Engineering, Design & Selection : PEDS|January 8, 2010
ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies)Tove Olafsen, Shannon J Sirk, David J Betting, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 1998
Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humansT L Odom-Maryon, L E Williams, A Chai, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1989
Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to manS M Larson, A Raubitschek, J C Reynolds, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2008
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membraneScott E James, Philip D Greenberg, Michael C Jensen, et al.
Annals of Internal Medicine|August 15, 1990
Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapyJ M Pluda, R Yarchoan, E S Jaffe, et al.
Pageof 9

Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
Cancer Research|February 1, 1990
Innovations that influence the pharmacology of monoclonal antibody guided tumor targetingJ Schlom, P H Hand, J W Greiner, et al.
Journal of Immunological Methods|June 1, 2001
Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applicationsP J Yazaki, L Shively, C Clark, et al.
Bioconjugate Chemistry|April 21, 2001
Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragmentsP J Yazaki, A M Wu, S W Tsai, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|November 1, 1992
A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapyJ R Lange, A A Raubitschek, B A Pockaj, et al.
Medical Physics|June 9, 1999
Intrapatient consistency of imaging biodistributions and their application to predicting therapeutic doses in a phase I clinical study of 90Y-based radioimmunotherapyK G Clarke, T L Odom-Maryon, L E Williams, et al.
Protein Engineering, Design & Selection : PEDS|January 8, 2010
ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies)Tove Olafsen, Shannon J Sirk, David J Betting, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 1998
Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humansT L Odom-Maryon, L E Williams, A Chai, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1989
Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to manS M Larson, A Raubitschek, J C Reynolds, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2008
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membraneScott E James, Philip D Greenberg, Michael C Jensen, et al.
Annals of Internal Medicine|August 15, 1990
Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapyJ M Pluda, R Yarchoan, E S Jaffe, et al.
Pageof 9